Form 4: Lineage Cell Therapeutics CEO Brian Culley Buys 10,000 Shares

Lineage Cell Therapeutics' CEO, Brian M. Culley, acquired 10,000 shares of the company's common stock at an average price of $1.05 per share on May 24, 2024.

Summary

• On May 24, 2024, Brian M. Culley, the President and CEO of Lineage Cell Therapeutics, Inc., purchased 10,000 shares of the company's common stock.
• The shares were bought at a weighted average price of $1.05, with individual prices ranging from $1.05 to $1.06.
• Following the transaction, Culley directly owns 154,842 shares of Lineage Cell Therapeutics.
• The purchase was disclosed in a Form 4 filing with the Securities and Exchange Commission.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. The CEO's purchase suggests confidence, but it's a relatively small transaction.

Positives

• The CEO's purchase of shares may signal confidence in the company's future prospects.

Industry Context

Insider buying is often seen as a positive sign, suggesting that a company's leadership believes the stock is undervalued. However, it's just one factor to consider when evaluating a company's potential.

Stakeholder Impact

• The CEO's share purchase could have a slightly positive impact on shareholder sentiment.

Key Dates